Pharma commercial teams see real ROI
More patients with a rare heart condition were identified by uncovering patients who were most likely mis-diagnosed
More scripts of a rare disease treatment were written by HCPs that Clarify scored as high-opportunity
Patients identified at high risk of non-adherence to infusion therapy by using social determinants of health data
Life sciences analytics, queryable in seconds
Enhance your brand’s performance throughout its lifecycle with this RWE software. We put commercial insights in your hands instantly. The intuitive, self-service interface lets you interrogate the platform’s 300M+ SDoH-decorated, payer-complete longitudinal patient journeys to refine patient cohorts and HCP targeting and puts RWE directly into your CRM.
Whether you are assessing the potential of a partnership deal or exploring a new market opportunity, this pharma analytics software gives you the inputs you need to gauge true value, in seconds. Using its self-service capabilities, you can build precise patient cohorts, slice and dice them by clinical and non-clinical characteristics, and understand treating HCPs.
Optimizing market access depends on in-depth payer insights. Acclaimed by Frost & Sullivan as life sciences’ most innovative RWE solution, this cloud software delivers on-demand payer insights to enable instant exploration of market dynamics and demonstration of therapeutic value to strengthen market access strategies. Learn about our complete Growth Suite of products for pharma commercial teams.
Real-world, social determinants of health (SDoH) insights can go a long way to making diversity in clinical trials a reality. Our RWE software delivers 400+ social determinants of health (SDoH) insights across >80% of the US population to help you select the sites and investigators that have the best opportunity to recruit diverse patients.
Pfizer and Clarify talk data strategies for commercialization
Pfizer and Clarify Health sat down with HLTH to talk about creating data-driven value stories for new therapies. Hear what Bhash Parasuraman, Vice President and BU Lead, Rare Disease Patient & Health Impact, Pfizer and Manisha Gulati, of Clarify Health, have to say.